PeterMD Review
Best for: men seeking flat-priced compounded GLP-1 access alongside TRT or peptide therapy
PeterMD is a men's telehealth platform offering compounded GLP-1 weight loss medications (semaglutide and tirzepatide, often with B12). Also covers TRT, peptide therapy, sexual health, and anti-aging treatments. Transparent monthly pricing with no insurance required.
Medium confidence · Last verified 2026-04-14 via websearch-multi-source · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
PeterMD is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
PeterMD prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Compounded Semaglutide (intro, first 2 months) | compounded | $135 |
| Compounded Semaglutide (ongoing) | compounded | $165 |
| Compounded Tirzepatide | compounded | $229 |
✓ Pros
- •Flat pricing across semaglutide dose tiers (0.25mg through 2.4mg)
- •Both semaglutide and tirzepatide available
- •No long-term commitment after the 2-month intro period
- •Month-to-month cancellation via patient portal, no cancellation fee
- •Covers men's-health adjacencies (TRT, peptides, ED, anti-aging) in one account
✗ Cons
- •Initial $270 two-month payment is non-refundable
- •Not available in 8 states (AL, AR, CA, HI, ID, MI, NC, TX)
- •Men's-only branding — will not appeal to women seeking GLP-1 access
- •Pharmacy partner and named clinicians not publicly disclosed
Ready to start with PeterMD?
Starting at $135/month. See current pricing and start your free consultation.
Sources & methodology
Our PeterMD review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to PeterMD
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Ready to start with PeterMD?
Starting at $135/month. See current pricing and start your free consultation.